{"id":"W2995123342","doi":"10.1016/j.jtho.2019.12.107","title":"PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee","year":2019,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":345,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Genentech; Takeda Pharmaceuticals U.S.A.; Meso Scale Diagnostics; AbbVie; Chugai Pharmaceutical; Roche; EMD Serono; Novartis; MedImmune; Agilent Technologies; GlaxoSmithKline; Merck; Bayer; Bayer Corporation; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Medicine; Companion diagnostic; Lung cancer; Immunohistochemistry; Oncology; Cancer; Clinical trial; Pathology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001898551,0.00036426,0.002983408,0.0002980553,0.00007564048,0.00001935897,0.0004777479,0.0006780794,0.000205676],"category_scores_gemma":[0.0007444787,0.0002114495,0.0009490091,0.0003998429,0.0001785769,0.00006919771,0.00007626995,0.001532938,0.000006296207],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00257004,"about_ca_system_score_gemma":0.003539805,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004513731,"about_ca_topic_score_gemma":0.0002794057,"domain_scores_codex":[0.9969927,0.0007243744,0.001352921,0.0003224963,0.0002229553,0.0003845363],"domain_scores_gemma":[0.9929663,0.003867891,0.002205569,0.0003762069,0.0005014521,0.00008261381],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002654363,0.0001559504,0.0004050604,0.002048702,0.001100324,0.000272332,0.0006147987,0.00000228799,0.00003576399,0.000006866596,0.01555686,0.9771467],"study_design_scores_gemma":[0.00173027,0.001807217,0.001452168,0.0167743,0.004811712,0.002028957,0.000698003,0.00002342837,0.000003340532,0.0001015387,0.9703251,0.0002439283],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0005454417,0.9901395,0.00005918594,0.004194914,0.002810897,0.00144002,0.0001952892,0.000008267546,0.0006064287],"genre_scores_gemma":[0.00009119249,0.9942034,0.001738509,0.001102565,0.002110725,0.00008789107,0.0000183589,0.00006405061,0.0005832888],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9769028,"threshold_uncertainty_score":0.8622661,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08695334608872189,"score_gpt":0.500247038117566,"score_spread":0.4132936920288441,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}